Analysts Offer Insights on Healthcare Companies: Adamas Pharmaceuticals (NASDAQ: ADMS) and Aeglea Biotherapeutics (NASDAQ: AGLE)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adamas Pharmaceuticals (ADMSResearch Report) and Aeglea Biotherapeutics (AGLEResearch Report).

Adamas Pharmaceuticals (ADMS)

Needham analyst Serge Belanger maintained a Hold rating on Adamas Pharmaceuticals today. The company’s shares closed last Monday at $4.57, close to its 52-week low of $3.35.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.5% and a 39.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, KalVista Pharmaceuticals, and Zynerba Pharmaceuticals.

Adamas Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $12.50.

See today’s analyst top recommended stocks >>

Aeglea Biotherapeutics (AGLE)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Aeglea Biotherapeutics today and set a price target of $20.00. The company’s shares closed last Monday at $7.82.

According to TipRanks.com, White is a 5-star analyst with an average return of 14.3% and a 49.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aeglea Biotherapeutics with a $16.67 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.